Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes
- 1 December 2019
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 38 (12) , 1268-1274
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant RecipientsInfectious Disease Clinics of North America, 2018
- Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant RecipientsTransplantation, 2015
- Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipientInternational Journal of Infectious Diseases, 2014
- Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipientsBMC Infectious Diseases, 2013
- Rapid Detection of Human Cytomegalovirus UL97 and UL54 Mutations Directly from Patient SamplesJournal of Clinical Microbiology, 2013
- Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trialThe Journal of Heart and Lung Transplantation, 2011
- Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung TransplantationAnnals of Internal Medicine, 2010
- Cytomegalovirus Resistance Testing: Pitfalls and Problems for the ClinicianClinical Infectious Diseases, 2010
- Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung TransplantationAmerican Journal of Transplantation, 2004
- Delay of CMV infection in high‐risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovirClinical Transplantation, 2004